|
|
Article: Early Use of Pfizer's Inspra(R) (Eplerenone) Significantly Reduced Death Rates Among Heart Attack Patients With Reduced Heart Muscle Function and Signs of Heart Failure.
- Article from:
- PR Newswire Europe
- Article date:
- August 8, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, August 8 /PRNewswire/ --
- Patient Survival Benefits Demonstrated Within 30 Days of Initial Treatment
Use of Inspra(R) (eplerenone) reduced the risk of early death in patients who have had a heart attack complicated by reduced heart muscle function (known as left ventricular systolic dysfunction [LVSD]) and heart failure. These data were published in the August 2 edition of the Journal of the American College of Cardiology (JACC).
Heart failure accompanying a heart attack is a leading predictor of in-hospital death and is associated with a three-to four-fold increase in 30-day and six-month mortality compared to heart attack ...